Sign Out
Women of childbearing potential should avoid becoming pregnant while being treated with Bortezomib. No placental transfer studies have been conducted with bortezomib. There are no adequate and well-controlled studies in pregnant women. If Bortezomib is used during pregnancy, or if the patient becomes pregnant while receiving this drug, the patient should be apprised of the potential hazard to the fetus. Patients should be advised to use effective contraceptive measures to prevent pregnancy and to avoid breastfeeding during treatment with Bortezomib.
Nursing Mothers: It is not known whether bortezomib is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from Bortezomib, women should be advised against breastfeeding while being treated with Bortezomib.
Lanjutkan dengan Google